Anthropic Says Self-Grading Fails, Then Signs a Pharma AI Deal── The AI vendor's safety policy and pharma's verification duty are separate systems; the responsibility stays with the user

On September 16, 2026, Anthropic's policy chief Sarah Heck said AI companies cannot operate on an honor code, and on the same day Anthropic announced a drug discovery AI partnership with a major European pharmaceutical company. How should pharma verify AI products from a company that admits it cannot check its own homework? The AI vendor's safety policy and pharma's legal verification duty are separate systems, and pharma must integrate AI output verification into its existing quality framework.

01Anthropic began supplying AI to pharma on the same day it called for regulation

Sarah Heck stated plainly: "We can't be checking our own homework, and that's very clear." This was an acknowledgment from within an AI company that self-regulation alone cannot guarantee safety.

On the same day, Anthropic announced a drug discovery partnership with a major European pharmaceutical company. The collaboration will use Claude's models and a research workbench to support candidate compound identification and biological reasoning. The pharmaceutical company had already established AI partnerships with other providers, making this part of a broader pattern of AI integration into drug discovery workflows. An AI company calling for regulation entered a domain where regulation has not yet caught up. The simultaneity is the crux of the matter: the same organization that publicly acknowledged the limits of self-regulation began supplying its products to one of the most heavily regulated industries.

02Outputs from an AI company that admits it cannot check its own homework become drug discovery inputs

The statement about not checking one's own homework acknowledged the limits of leaving output verification solely to the developer. The AI company itself said its verification capacity has an upper bound.

That same AI now generates inputs for drug discovery decisions. When biological reasoning used in compound selection comes from an AI model, who verifies that reasoning? The AI company has stated it cannot fully check its own work. External regulators have not yet established specific requirements for AI in drug discovery. The pharmaceutical company's internal quality systems were designed before AI became a contributor to research outputs. Into this gap, the verification responsibility falls squarely on the user, whether or not the user has built the systems to carry it.

03AI errors at the drug discovery stage can reach the evidence base of post-launch materials

Errors in AI-generated reasoning at the drug discovery stage do not necessarily stay contained in research. Biased compound selection can affect clinical trial design, alter the content of package inserts at approval, and ultimately reach the evidence base used in post-launch promotional materials.

Drug discovery and material review appear to be separate workflows, but the data flows in one direction. If AI is involved upstream and that involvement cannot be traced, the means to verify the legitimacy of evidence downstream in material review disappears. A reviewer examining a promotional material five years after the compound was selected may have no way to know that the efficacy figure in front of them was derived from an AI-assisted analysis, let alone to verify whether that analysis was correct.

04The AI vendor's safety policy and pharma's legal verification duty differ in legal basis and oversight body

The alignment tests, red-team evaluations, and incident disclosures that AI companies perform are voluntary measures under their own safety policies. They may be thorough, and they may be conducted in good faith, but they do not carry legal force in the pharmaceutical regulatory context. The verification duties pharma bears under pharmaceutical law, GxP-compliant management frameworks, and the obligation to ensure accuracy in package inserts rest on an entirely different legal foundation with different oversight bodies. A red-team evaluation does not satisfy a GxP audit requirement. An incident disclosure does not fulfill a regulatory submission obligation. Neither system substitutes for the other, and conflating them creates the illusion of coverage where a gap actually exists.

05Extending the source-checking step in material review accommodates AI output verification within existing systems

When AI is involved in generating sources or summarizing figures, the source-checking step already embedded in material review can be extended. Rather than building a new system, add a step of cross-checking AI output against original data to the existing workflow. The number of items to verify increases, but the method does not change. A reviewer who already checks that a cited publication exists and that its conclusions match the material's claims is performing the same cognitive operation when confirming that an AI-extracted figure matches the original dataset. The skill is the same. What changes is the awareness that a machine, rather than a human colleague, produced the intermediate summary.

06The more a vendor promotes safety, the more likely the user is to skip its own verification

The more actively an AI company communicates its safety efforts, the more easily the user assumes that precautions have already been taken. The vendor's safety messaging can function as a reason for the user to abbreviate its own verification, creating a structural gap.

Responsibility is distributed across three parties: the developer, the provider, and the user. The developer is responsible for model safety, the provider for API operations, and the user for the correctness of outputs. When each of the three assumes the other two are handling it, no sufficient verification remains at any stage. This is not a hypothetical scenario. It is the default configuration of any enterprise AI deployment where roles and responsibilities have not been explicitly negotiated and documented.

07Integrate vendor assessment, output verification, and record retention into existing quality systems

These three actions sit on the extension of quality systems pharma already maintains. Vendor assessment fits within existing supplier evaluation, output cross-checking extends source verification, and record retention uses the existing document management infrastructure. Adopting AI does not require building a new framework; it requires carefully adding AI-specific verification and documentation steps to the processes already in place.

Even when the AI comes from a company that acknowledges safety limits, pharma's verification duty remains its own. What matters is not the vendor's policy but whether your review process includes a step to cross-check AI outputs.